Shares of Cartesian Therapeutics rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year. Shares were up 29% to $8.81 in Monday afternoon ...
Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravisPhase 2 TRITON trial of Descartes-08 in ...
Fintel reports that on March 9, 2026, Cantor Fitzgerald upgraded their outlook for Cartesian Therapeutics (NasdaqGM:RNAC) from Neutral to Overweight. Analyst Price Forecast Suggests 303.82% Upside As ...
The use of Cartesian and six-axis robots, as well as selective-compliance-articulated robot arms (SCARAs) is on the rise. They automate tasks to accelerate cycle times, increase throughput, and ...
FREDERICK, Md., March 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“we”, the “Company” or “Cartesian”), a late clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results